LGND — Ligand Pharmaceuticals Incorporated Share News
0.000.00%
Last trade - 00:00- $5.95bn
- $5.72bn
- $215.02m
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan
U.S. STOCKS ON THE MOVE-Bath & Body Works, Avis Budget, Cerebras
U.S. STOCKS ON THE MOVE-Boundless Bio, Galectin, UniQure
U.S. STOCKS ON THE MOVE-Chipmakers, CDW, Accenture
Ligand Pharma slips after upsized $625 mln convertible debt offering
U.S. STOCKS ON THE MOVE-Abbvie, AMC, Getty
U.S. STOCKS ON THE MOVE-Getty Images, Ecarx, Maplight Therapeutics
U.S. STOCKS ON THE MOVE-Definium, Regenxbio, Arcosa
Ligand Pharma eases from record on $550 mln convertible debt deal
Brief: Ligand Announces Proposed Offering Of $550 Million Of Convertible Senior Notes Due 2031
Ligand Q1 revenue rises 14% on royalty growth
U.S. RESEARCH ROUNDUP-Commvault Systems, Domino's Pizza, Organon & Co
Deals of the day-Mergers and acquisitions
Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million (updated)
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
Brief: Ligand Pharmaceuticals Is Buying Xoma For Nearly $740 Million - WSJ